New hope for fewer side effects in transplant patients?
NCT ID NCT06034925
Summary
This study compared two different drug regimens to prevent a common and serious viral infection (CMV) in people who recently received a kidney transplant and are at high risk. Researchers wanted to see if a newer drug, maribavir, caused fewer side effects like low white blood cell counts than the standard drug, valganciclovir, while being just as good at preventing infection. The trial involved 70 adult kidney transplant recipients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT COMPLICATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.